S&P 500   5,085.38 (+0.31%)
DOW   38,922.20 (-0.07%)
QQQ   438.41 (+0.72%)
AAPL   180.55 (-0.48%)
MSFT   409.32 (+0.39%)
META   488.36 (+0.90%)
GOOGL   137.23 (+0.62%)
AMZN   174.87 (+0.99%)
TSLA   200.66 (-0.68%)
NVDA   791.54 (+1.92%)
NIO   5.68 (+4.60%)
AMD   189.29 (+7.22%)
BABA   74.23 (-0.48%)
T   17.04 (+0.47%)
F   12.38 (+0.65%)
MU   90.04 (+0.37%)
CGC   3.31 (-1.49%)
GE   155.79 (+0.12%)
DIS   111.12 (+0.29%)
AMC   4.28 (-14.23%)
PFE   26.83 (-0.78%)
PYPL   60.31 (+0.10%)
XOM   104.66 (+0.33%)
S&P 500   5,085.38 (+0.31%)
DOW   38,922.20 (-0.07%)
QQQ   438.41 (+0.72%)
AAPL   180.55 (-0.48%)
MSFT   409.32 (+0.39%)
META   488.36 (+0.90%)
GOOGL   137.23 (+0.62%)
AMZN   174.87 (+0.99%)
TSLA   200.66 (-0.68%)
NVDA   791.54 (+1.92%)
NIO   5.68 (+4.60%)
AMD   189.29 (+7.22%)
BABA   74.23 (-0.48%)
T   17.04 (+0.47%)
F   12.38 (+0.65%)
MU   90.04 (+0.37%)
CGC   3.31 (-1.49%)
GE   155.79 (+0.12%)
DIS   111.12 (+0.29%)
AMC   4.28 (-14.23%)
PFE   26.83 (-0.78%)
PYPL   60.31 (+0.10%)
XOM   104.66 (+0.33%)
S&P 500   5,085.38 (+0.31%)
DOW   38,922.20 (-0.07%)
QQQ   438.41 (+0.72%)
AAPL   180.55 (-0.48%)
MSFT   409.32 (+0.39%)
META   488.36 (+0.90%)
GOOGL   137.23 (+0.62%)
AMZN   174.87 (+0.99%)
TSLA   200.66 (-0.68%)
NVDA   791.54 (+1.92%)
NIO   5.68 (+4.60%)
AMD   189.29 (+7.22%)
BABA   74.23 (-0.48%)
T   17.04 (+0.47%)
F   12.38 (+0.65%)
MU   90.04 (+0.37%)
CGC   3.31 (-1.49%)
GE   155.79 (+0.12%)
DIS   111.12 (+0.29%)
AMC   4.28 (-14.23%)
PFE   26.83 (-0.78%)
PYPL   60.31 (+0.10%)
XOM   104.66 (+0.33%)
S&P 500   5,085.38 (+0.31%)
DOW   38,922.20 (-0.07%)
QQQ   438.41 (+0.72%)
AAPL   180.55 (-0.48%)
MSFT   409.32 (+0.39%)
META   488.36 (+0.90%)
GOOGL   137.23 (+0.62%)
AMZN   174.87 (+0.99%)
TSLA   200.66 (-0.68%)
NVDA   791.54 (+1.92%)
NIO   5.68 (+4.60%)
AMD   189.29 (+7.22%)
BABA   74.23 (-0.48%)
T   17.04 (+0.47%)
F   12.38 (+0.65%)
MU   90.04 (+0.37%)
CGC   3.31 (-1.49%)
GE   155.79 (+0.12%)
DIS   111.12 (+0.29%)
AMC   4.28 (-14.23%)
PFE   26.83 (-0.78%)
PYPL   60.31 (+0.10%)
XOM   104.66 (+0.33%)

Aridis Pharmaceuticals (ARDS) News Today

$0.07
0.00 (-3.90%)
(As of 01:18 PM ET)
SourceHeadline
MarketBeat logoAridis Pharmaceuticals (NASDAQ:ARDS) vs. Imunon (NASDAQ:IMNN) Financial Survey
americanbankingnews.com - February 19 at 1:56 AM
bbc.co.uk logoIrish Cup: Institute's quarter-final place confirmed as IFA rejects Ards protest
bbc.co.uk - February 10 at 7:59 PM
finance.yahoo.com logoAridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024
finance.yahoo.com - December 15 at 9:07 PM
markets.businessinsider.com logoAridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update
markets.businessinsider.com - November 3 at 5:11 PM
finance.yahoo.com logoAridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update
finance.yahoo.com - November 3 at 5:11 PM
morningstar.com logoAridis Pharmaceuticals Inc ARDS
morningstar.com - November 1 at 4:04 PM
benzinga.com logoAridis Pharmaceuticals Stock (OTC:ARDS), Analyst Ratings, Price Targets, Predictions
benzinga.com - October 22 at 1:46 PM
msn.com logoHC Wainwright & Co. Maintains Aridis Pharmaceuticals (ARDS) Buy Recommendation
msn.com - October 21 at 1:44 PM
markets.businessinsider.com logoFDA’s Qualified Infectious Disease Product Designation Bolsters Aridis Pharmaceuticals’ Investment Appeal: An Analyst’s Buy Recommendation
markets.businessinsider.com - October 20 at 2:15 PM
finance.yahoo.com logoARDS Sep 2023 2.500 call
finance.yahoo.com - September 15 at 7:41 PM
finance.yahoo.com logoAridis Pharmaceuticals, Inc., Genetic Technologies Limited, and American Resources Corporation Interviews to Air on the RedChip Money Report(R) on Bloomberg TV
finance.yahoo.com - September 15 at 9:40 AM
investing.com logoAridis Pharma (ARDS) Earnings Dates & Reports
investing.com - August 21 at 10:59 PM
finance.yahoo.com logoAridis Pharmaceuticals Announces $2 Million Offering
finance.yahoo.com - August 2 at 9:42 AM
finance.yahoo.com logoWhy Are Aridis Pharmaceuticals Shares Moving Higher Today?
finance.yahoo.com - July 18 at 3:12 PM
finance.yahoo.com logoAridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301
finance.yahoo.com - July 17 at 6:32 PM
finance.yahoo.com logoAridis (ARDS) Up on Receiving FDA's QIDP Designation for AR-301
finance.yahoo.com - July 13 at 2:44 PM
finance.yahoo.com logoAridis’ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product (QIDP) Designation
finance.yahoo.com - July 12 at 2:04 PM
marketwatch.com logoAridis Pharmaceuticals' AR-301 Eligible for Consideration under FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)
marketwatch.com - June 22 at 5:22 PM
finance.yahoo.com logoAridis Pharmaceuticals' AR-301 Eligible for Consideration under FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)
finance.yahoo.com - June 20 at 12:47 PM
finanznachrichten.de logoAridis Pharmaceuticals, Inc.: Aridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business Update
finanznachrichten.de - June 9 at 9:37 AM
finance.yahoo.com logoAridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business Update
finance.yahoo.com - June 8 at 6:27 PM
benzinga.com logoAridis Pharmaceuticals Stock (NASDAQ:ARDS), Guidance and Forecast
benzinga.com - June 1 at 5:15 PM
finance.yahoo.com logoAridis Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study Design
finance.yahoo.com - May 31 at 10:51 AM
finance.yahoo.com logoAridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-Q
finance.yahoo.com - May 25 at 4:32 PM
finance.yahoo.com logoAridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-K
finance.yahoo.com - April 26 at 1:56 PM
bizjournals.com logoBig pharma, small drug maker spar over pneumonia drug deal
bizjournals.com - April 3 at 2:04 PM
finance.yahoo.com logoAridis Provides Corporate Update
finance.yahoo.com - March 31 at 8:13 PM
msn.com logoAstraZeneca Axes Pneumonia Drug Pact With Aridis
msn.com - March 29 at 4:37 PM
msn.com logoWhy Aridis Pharmaceuticals Shares Are Diving
msn.com - March 14 at 5:54 PM
marketwatch.com logoAridis Pharmaceuticals Shares Tumble After Stock Offering >ARDS
marketwatch.com - March 14 at 5:54 PM
msn.com logoAridis (ARDS) Stock Up as Cystic Fibrosis Study Meets Goals
msn.com - March 14 at 5:54 PM
finance.yahoo.com logoAridis Pharmaceuticals Announces $2.28 Million Registered Direct Offering of Common Stock
finance.yahoo.com - March 14 at 5:54 PM
msn.com logoAridis Skyrockets on Impressive Data In Cystic Fibrosis
msn.com - March 13 at 6:09 PM
msn.com logoAridis stock surges ~35% as lung disease drug AR-501 meets main goal in mid-stage study
msn.com - March 13 at 6:09 PM
finance.yahoo.com logoWhy Aridis Pharmaceuticals Shares Are Soaring Today
finance.yahoo.com - March 13 at 6:09 PM
marketwatch.com logoAridis Shares Rally Premarket on Positive Phase 2a Cystic Fibrosis Study >ARDS
marketwatch.com - March 13 at 8:57 AM
finance.yahoo.com logoAridis Meets Primary and Secondary Endpoints in Phase 2a Study of AR-501 in Cystic Fibrosis Patients
finance.yahoo.com - March 13 at 8:57 AM
finanznachrichten.de logoInterviews with Rail Vision, Aridis Pharmaceuticals, and Digital Ally to Air on Bloomberg U.S. on the RedChip Money Report
finanznachrichten.de - February 17 at 8:05 AM
finance.yahoo.com logoWhen Will Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) Breakeven?
finance.yahoo.com - February 15 at 7:41 AM
finance.yahoo.com logoIn virtuous cycle, foundation uses drug royalty riches to back new cystic fibrosis drug research in Bay Area
finance.yahoo.com - February 6 at 7:03 PM
finance.yahoo.com logoHere's Why Aridis Pharmaceuticals (ARDS) Is a Great 'Buy the Bottom' Stock Now
finance.yahoo.com - February 1 at 4:13 PM
markets.businessinsider.com logoAnalysts Offer Insights on Healthcare Companies: Ocuphire Pharma (OCUP), Aridis Pharmaceuticals (ARDS) and Acurx Pharmaceuticals (ACXP)
markets.businessinsider.com - January 27 at 8:30 AM
msn.com logoAridis stock slumps ~25% as antibody drug fails phase 3 trial in pneumonia
msn.com - January 26 at 9:52 AM
finance.yahoo.com logoAridis Reports Top-Line Results of the Phase 3 Double-Blinded, Superiority Trial of AR-301 For the Treatment of Staphylococcus aureus Ventilator Associated Pneumonia (VAP)
finance.yahoo.com - January 25 at 6:34 PM
marketbeat.com logo
marketbeat.com - January 25 at 4:11 PM
marketbeat.com logo
marketbeat.com - January 24 at 11:16 AM
finance.yahoo.com logoNew Approaches to Treating Infections in Cystic Fibrosis Patients - AR 501 Phase 2 Trial Update
finance.yahoo.com - January 17 at 7:06 PM
finance.yahoo.com logoAridis Pharmaceuticals to Discuss Topline Data from Phase 3 Study of AR-301 During Corporate Update Call on January 25
finance.yahoo.com - December 28 at 1:24 PM
finance.yahoo.com logo(Updated) Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation
finance.yahoo.com - December 12 at 5:26 PM
finance.yahoo.com logoAridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation
finance.yahoo.com - December 12 at 7:32 AM
Get Aridis Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARDS and its competitors with MarketBeat's FREE daily newsletter.



ARDS Media Mentions By Week

ARDS Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ARDS
News Sentiment

0.00

0.60

Average
Medical
News Sentiment

ARDS News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ARDS Articles
This Week

0

0

ARDS Articles
Average Week

Get Aridis Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARDS and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:ARDS) was last updated on 2/29/2024 by MarketBeat.com Staff